There is currently a major gap in guidance and patient preference literature on how decision makers can use patient preferences and how researchers can conduct fit-for-purpose studies that are more relevant to decision makers. The current regulatory and assessor landscape will be discussed including the European Union’s Innovative Medicines Initiative (IMI) and the Medical Device Innovation Consortium (MDIC). The task force is presenting their work to date with the request for feedback.
- In which decision contexts are patient preferences relevant?;
- How can preference studies be most relevant to decision makers?; and
- Which questions should be answered by the task force’s draft framework and preliminary recommendations?